NEW YORK (GenomeWeb) – Integrated Diagnostics is preparing to launch its second-generation Xpresys Lung test, a blood test to help assess whether lung nodules are likely benign or cancerous, in the second half of next year.

With Medicare coverage for the test in place, the company is hoping it will surpass the limited commercial success of its initial Xpresys Lung offering.

Indi is also submitting for publication results from its Panoptic study, a 33-center prospective trial of the test that CEO Albert Luderer said will support the company's commercialization efforts.

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try 360Dx Premium now.

You may already have institutional access!

Check if I qualify.

Already a 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.